Citations

Clear

2 citation(s) found for "Shapiro, William".

American Cochlear Implant Alliance Task Force Guidelines for Clinical Assessment and Management of Adult Cochlear Implantation for Single-Sided Deafness
Kocharyan, Arminé , Daher, Ghazal S. , Carlson, Matthew L. , Shapiro, William H., Snapp, Hillary , Firszt, Jill B. , Dillon, Margaret T.

Mayo Clinic

Ear & Hearing | August 22, 2022 | Volume: 43 | Issue: 6 | Pages: 1605-1619

10.1097/aud.0000000000001260 | PMID 35994570 Get It

The indications for cochlear implantation have expanded to include individuals with profound sensorineural hearing loss in the impaired ear and normal hearing (NH) in the contralateral ear, known as single-sided deafness (SSD). There are additional considerations for the clinical assessment and management of adult cochlear implant candidates and recipients with SSD as compared to conventional cochlear implant candidates with bilateral moderate to profound sensorineural hearing loss. The present report reviews the current evidence relevant to the assessment and management of adults with SSD. A systematic review was also conducted on published studies that investigated outcomes of cochlear implant use on measures of speech recognition in quiet and noise, sound source localization, tinnitus perception, and quality of life for this patient population. Expert consensus and systematic review of the current literature were combined to provide guidance for the clinical assessment and management of adults with SSD.
Abstract 4138: Five prognostic subgroups differ in expression of Akt pathway genes: Biomarkers for therapy selection
Joy, Anna , Ramesh, Archana , Bachoo, Robert , Shapiro, William, Smirnov, Ivan V. , Kim, Seungchan , Sarkaria, Jann N. , Ram, Prahlad T. , Mills, Gordon B. , Feuerstein, Burt G.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 71 | Issue: 8_Supplement | Pages: 4138-4138

10.1158/1538-7445.am2011-4138 Get It

Abstract Biomarkers that select patients for therapeutics would benefit clinical trial design and patient care. The Akt pathway is a therapeutic target in Glioblastoma Multiforme (GBM) and an important determinant of patient outcome. However, it is not known whether activity of this pathway varies among GBM tumors. To investigate we used Akt pathway genes from published GBM expression datasets. We detected 5 patterns of Akt pathway gene expression and these Akt subgroups correlated with prognosis. We analyzed networks within subgroups using both gene set enrichment analysis and a novel method that scores relevance based on both expression and local network connectivity (Komurov et al., PLoS Comput Biol. 2010 6:8, 1-10). The results suggest therapeutic targets within the individual subgroups. Furthermore, preliminary analysis indicates that human GBM xenograft models and primary human GBM manifest similar Akt subgroups. We are investigating rodent xenograft models of Akt subgroups to evaluate subgroup-specific drug sensitivity, and will present a method and examples of analysis integrating gene expression data from human GBM xenografts and primary human GBM. We hypothesize that Akt subgroups will help personalize treatment for GBM therapeutics. Supported by Barrow Neurological Foundation, Halle Family Foundation, and NIH 1 K01 NS064952-01A1 (AMJ). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4138. doi:10.1158/1538-7445.AM2011-4138